Cristian Moreno, CEO of Torque Metals (ASX:TOR), discusses the New Dawn Lithium project, the Paris Gold Project and Torque’s strategies and future plans. Paul Sanger: Hi, I’m Paul Sanger for the Finance News Network and today we’re talking to Torque Metals, ASX Code TOR, which has a market capitalization of around 30 million. Torque is […]
New lithium and gold opportunities with Torque Metals’ Cristian Moreno Read More »
Star Combo Pharma (ASX:S66) CEO Su Zhang presents at the Beijing Two Zones Investment Promotion Webinar (Australia Roadshow), May 2024.
Beijing-Australia Small Cap Investment Webinar, May 2024 – Star Combo Pharma Read More »
EZZ Life Science Holdings (ASX:EZZ) Chair Glenn Cross presents at the Beijing Two Zones Investment Promotion Webinar (Australia Roadshow), May 2024.
Beijing-Australia Small Cap Investment Webinar, May 2024 – EZZ Life Science Holdings Read More »
Hiremii (ASX:HMI) Managing Director & CEO Andrew Hornby presents at the Beijing Two Zones Investment Promotion Webinar (Australia Roadshow), May 2024.
Beijing-Australia Small Cap Investment Webinar, May 2024 – Hiremii Read More »
Finexia Financial Group (ASX:FNX) CEO & Director Patrick Bell presents at the Beijing Two Zones Investment Promotion Webinar (Australia Roadshow), May 2024.
Beijing-Australia Small Cap Investment Webinar, May 2024 – Finexia Financial Group Read More »
Hazer Group (ASX:HZR) CEO & Managing Director Glenn Corrie presents at the Beijing Two Zones Investment Promotion Webinar (Australia Roadshow), May 2024.
Beijing-Australia Small Cap Investment Webinar, May 2024 – Hazer Group Read More »
Dotz Nano (ASX:DTZ) Chairman Bernie Brookes presents at the Beijing Two Zones Investment Promotion Webinar (Australia Roadshow), May 2024.
Beijing-Australia Small Cap Investment Webinar, May 2024 – Dotz Nano Read More »
INOVIQ (ASX:IIQ) CEO Dr Leearne Hinch presents at the Beijing Two Zones Investment Promotion Webinar (Australia Roadshow), May 2024.
Beijing-Australia Small Cap Investment Webinar, May 2024 – INOVIQ Read More »
Another struggling Kiwi-listed company is Synlait (ASX:SM1); its market position has deteriorated with weaker sales, high costs, and a major falling out with its major customer, A2 Milk. Synlait shares are down 40% this year and more than 70% in the last 12 months because of a conjunction of events that have put it under
Synlait’s financial challenges and road to recovery Read More »
Immutep (ASX:IMM) teams up with MSD to study Efti alongside KEYTRUDA® in a pivotal phase III trial, TACTI-004. This trial plans to enrol about 750 patients with 1L NSCLC, irrespective of PD-L1 expression, expanding the potential anti-PD-1 therapy market. Shares are on a trading halt and last traded at 45 cents. INOVIQ (ASX:IIQ) has successfully
Stocks of the Hour: Immutep, INOVIQ, Eastern Metals Read More »
